UC-Riverside: “Ecopipam reduces stuttering symptoms in proof-of-concept trial”

According to reporting by Iqbal Pittalwala at the University of California, Riverside, a team led by a UC-Riverside psychiatrist “has tested the orally administered investigational medication ecopipam on adults who stutter in an open-label, uncontrolled clinical trial and found that it reduced their stuttering symptoms from the start of therapy after eight weeks of dosing. Positive results included increased speech fluency, faster reading completion, and shortened duration of stuttering events.”

“Ecopipam was well tolerated by the study participants,” said Dr. Gerald Maguire, chair of psychiatry and neuroscience in the UCR School of Medicine, who led the study published this month in the Annals of Clinical Psychiatry.

Read More…